Rabbit JAK2 Polyclonal Antibody | anti-JAK2 antibody

JAK2 Antibody

Cat. Num. AAA153571

• Gene Names: JAK2; JTK10; THCYT3
• Reactivity: Human, Mouse, Rat
• Applications: ELISA, Western Blot, Immunohistochemistry
• Purity: JAK2 antibody is affinity chromatography purified via peptide column.
• Synonyms: JAK2; Polyclonal Antibody; JAK2 Antibody; Janus kinase 2; JTK10; THCYT3; anti-JAK2 antibody

• Host: Rabbit
• Reactivity: Human, Mouse, Rat
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: JAK2 antibody is human, mouse and rat reactive. JAK2 antibody is predicted to not cross-react with other members of the JAK family of proteins.
• Purity/Purification: JAK2 antibody is affinity chromatography purified via peptide column.
• Form/Format: Liquid
• Concentration: 1 mg/mL (varies by lot)
• Sequence Length: 1132

• Applicable Applications for anti-JAK2 antibody: ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)
• Application Notes: JAK2 antibody can be used for detection of JAK2 by Western blot at 1 - 2 mug/ml. Antibody can also be used for immunohistochemistry starting at 5 mug/mL.
• Conjugate: Unconjugated
• Immunogen: JAK2 antibody was raised against an 18 amino acid peptide near the carboxy terminus of human JAK2.
• Buffer: JAK2 antibody is supplied in PBS containing 0.02% sodium azide.
• Preparation and Storage: JAK2 antibody can be stored at 4 degree C for three months and -20 degree C, stable for up to one year.

Western Blot (WB)

(Western blot analysis of JAK2 in HeLa cell lysate with JAK2 antibody at 1 μg/ml.)

Immunohistochemistry (IHC)

(Immunohistochemistry of JAK2 in mouse kidney tissue with JAK2 antibody at 5 μg/ml.)

Related Product Information for anti-JAK2 antibody

JAK2 is a member of the JAK family of kinases that also include JAK1, JAK3, and TYK2 (1,2). JAK kinases are activated following tyrosine phosphorylation of cytokine receptors after ligand binding. JAK2 activation promotes the recruitment and phosphorylation of STAT3 and STAT5. These transcription factors then translocate to the nucleus where they bind specific DNA promoter sequences resulting in the transcription of genes that regulate cell proliferation, differentiation, and apoptosis (3). Mice with a disrupted JAK2 gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis (4).

NCBI and Uniprot Product Information

• NCBI GI #: 4826776
• NCBI GeneID: 3717
• NCBI Accession #: NP_004963
• NCBI GenBank Nucleotide #: NM_004972.3
• UniProt Accession #: O60674; O14636; O75297
• Molecular Weight: Predicted: 125 kDa; ; Observed: 125 kDa
• NCBI Official Full Name: tyrosine-protein kinase JAK2
• NCBI Official Synonym Full Names: Janus kinase 2
• NCBI Official Symbol: JAK2
• NCBI Official Synonym Symbols: JTK10; THCYT3
• NCBI Protein Information: tyrosine-protein kinase JAK2; JAK-2; Janus kinase 2 (a protein tyrosine kinase)
• UniProt Protein Name: Tyrosine-protein kinase JAK2
• Protein Family: Tyrosine-protein kinase
• UniProt Gene Name: JAK2
• UniProt Synonym Gene Names: JAK-2
• UniProt Entry Name: JAK2_HUMAN

NCBI Description

This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq, Jul 2008]

Uniprot Description

JAK2: a non-receptor tyrosine-kinase involved in a specific subset of cytokine receptor signaling pathways, including IL-3, -5 and GM-CSF. Interacts with IL23R, SKB1 and STAM2. It has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. Fusion of Jak2 to TEL1 (ETV6) by t(9;12)(p24;p13) causes myeloproliferative disease in humans and mouse models. The Jak inhibitor AG490 inhibits constitutive Jak2 phosphorylation and causes apoptosis in cells from breast cancer and relapsing acute lymphoblastic leukemia. A single activating mutation is associated with several hematological malignancies. Inhibitor: AG490.

Protein type: Protein kinase, TK; Kinase, protein; EC 2.7.10.2; Oncoprotein; Protein kinase, tyrosine (non-receptor); TK group; JakA family

Chromosomal Location of Human Ortholog: 9p24

Cellular Component: nucleoplasm; extrinsic to internal side of plasma membrane; cytoskeleton; nuclear matrix; cytoplasm; caveola; nucleus; cytosol; lipid raft

Molecular Function: protein C-terminus binding; histone binding; non-membrane spanning protein tyrosine kinase activity; acetylcholine receptor binding; protein kinase binding; interleukin-12 receptor binding; protein kinase activity; protein binding; growth hormone receptor binding; peptide hormone receptor binding; protein-tyrosine kinase activity; insulin receptor substrate binding; heme binding; phosphoinositide 3-kinase binding; type 1 angiotensin receptor binding; SH2 domain binding; ATP binding; receptor binding

Biological Process: establishment and/or maintenance of chromatin architecture; positive regulation of nitric oxide biosynthetic process; activation of MAPKK activity; tyrosine phosphorylation of Stat3 protein; response to lipopolysaccharide; tyrosine phosphorylation of JAK2 protein; enzyme linked receptor protein signaling pathway; protein amino acid phosphorylation; positive regulation of tyrosine phosphorylation of Stat3 protein; response to antibiotic; regulation of apoptosis; elevation of cytosolic calcium ion concentration; tumor necrosis factor-mediated signaling pathway; erythrocyte differentiation; mesoderm development; negative regulation of neuron apoptosis; positive regulation of DNA binding; positive regulation of cell activation; positive regulation of protein import into nucleus, translocation; axon regeneration; positive regulation of insulin secretion; JAK-STAT cascade; positive regulation of tumor necrosis factor production; tyrosine phosphorylation of Stat5 protein; positive regulation of phosphoinositide 3-kinase cascade; tyrosine phosphorylation of STAT protein; positive regulation of peptidyl-tyrosine phosphorylation; response to hydroperoxide; mineralocorticoid receptor signaling pathway; tyrosine phosphorylation of Stat1 protein; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription factor activity; positive regulation of cell differentiation; positive regulation of nitric-oxide synthase biosynthetic process; positive regulation of phosphoprotein phosphatase activity; peptidyl-tyrosine phosphorylation; hormone-mediated signaling; negative regulation of heart contraction; apoptosis; protein amino acid autophosphorylation; platelet-derived growth factor receptor signaling pathway; signal transduction; host programmed cell death induced by symbiont; negative regulation of cell proliferation; actin filament polymerization; positive regulation of cell proliferation; cell differentiation; STAT protein nuclear translocation; caspase activation; cell migration; cytokine and chemokine mediated signaling pathway; negative regulation of DNA binding; regulation of cell proliferation; G-protein coupled receptor protein signaling pathway; positive regulation of interleukin-1 beta production; positive regulation of tyrosine phosphorylation of Stat5 protein; regulation of inflammatory response; innate immune response; negative regulation of cell-cell adhesion; cell motility; blood coagulation; induction of apoptosis by oxidative stress; positive regulation of cell migration; positive regulation of inflammatory response

Disease: Polycythemia Vera; Myelofibrosis; Erythrocytosis, Familial, 1; Budd-chiari Syndrome; Thrombocythemia 3